BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 33569431)

  • 1. Distinctive genomic characteristics in
    He J; Ouyang W; Zhao W; Shao L; Li B; Liu B; Wang D; Han-Zhang H; Zhang Z; Shao L; Li W
    Ann Transl Med; 2021 Jan; 9(2):129. PubMed ID: 33569431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.
    Ambrosini M; Rousseau B; Manca P; Artz O; Marabelle A; André T; Maddalena G; Mazzoli G; Intini R; Cohen R; Cercek A; Segal NH; Saltz L; Varghese AM; Yaeger R; Nusrat M; Goldberg Z; Ku GY; El Dika I; Margalit O; Grinshpun A; Kasi P; Schilsky R; Lutfi A; Shacham-Shmueli E; Khan Afghan M; Weiss L; Westphalen CB; Conca V; Decker B; Randon G; Elez E; Fakih M; Schrock AB; Cremolini C; Jayachandran P; Overman MJ; Lonardi S; Pietrantonio F
    Ann Oncol; 2024 May; ():. PubMed ID: 38777726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive analysis of POLE/POLD1 genomic alterations in colorectal cancer.
    Mosalem O; Coston TW; Imperial R; Mauer E; Thompson C; Yilma B; Bekaii-Saab TS; Stoppler MC; Starr JS
    Oncologist; 2024 May; ():. PubMed ID: 38776551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of
    Zhu M; Cui H; Zhang L; Zhao K; Jia X; Jin H
    Transl Cancer Res; 2022 Jan; 11(1):193-205. PubMed ID: 35261896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. POLE/POLD1 mutation and tumor immunotherapy.
    Ma X; Dong L; Liu X; Ou K; Yang L
    J Exp Clin Cancer Res; 2022 Jul; 41(1):216. PubMed ID: 35780178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct mutational profile and immune microenvironment in microsatellite-unstable and
    Hwang HS; Kim D; Choi J
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant
    Keshinro A; Vanderbilt C; Kim JK; Firat C; Chen CT; Yaeger R; Ganesh K; Segal NH; Gonen M; Shia J; Stadler Z; Weiser MR
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population.
    Yao J; Gong Y; Zhao W; Han Z; Guo S; Liu H; Peng X; Xiao W; Li Y; Dang S; Liu G; Li L; Huang T; Chen S; Song L
    Sci Rep; 2019 Oct; 9(1):15767. PubMed ID: 31673068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating POLE/POLD1 mutated for immunotherapy treatment planning of advanced stage non-small cell lung cancer.
    Zheng S; Cao Y; Randall J; Yu H; Thomas TO
    Thorac Cancer; 2023 Aug; 14(23):2269-2274. PubMed ID: 37345618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
    Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
    Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity.
    Ma X; Riaz N; Samstein RM; Lee M; Makarov V; Valero C; Chowell D; Kuo F; Hoen D; Fitzgerald CWR; Jiang H; Alektiar J; Alban TJ; Juric I; Parthasarathy PB; Zhao Y; Sabio EY; Verma R; Srivastava RM; Vuong L; Yang W; Zhang X; Wang J; Chu LK; Wang SL; Kelly DW; Pei X; Chen J; Yaeger R; Zamarin D; Zehir A; Gönen M; Morris LGT; Chan TA
    Nat Genet; 2022 Jul; 54(7):996-1012. PubMed ID: 35817971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
    Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ
    Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases.
    Li Y; Yang X; Zhu W; Xu Y; Ma J; He C; Wang F
    Cancer Cell Int; 2022 Nov; 22(1):347. PubMed ID: 36371186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?
    Vegivinti CTR; Gonzales Gomez C; Syed M; Ferrell M; Cheng S; Singhi A; Saeed A; Sahin IH
    Expert Opin Biol Ther; 2023; 23(7):595-601. PubMed ID: 37318031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers.
    Ying J; Yang L; Yin JC; Xia G; Xing M; Chen X; Pang J; Wu Y; Bao H; Wu X; Shao Y; Zhu L; Cheng X
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy.
    Zheng X; Lin J; Xiong J; Guan Y; Lan B; Li Y; Gao X; Fei Z; Chen L; Chen L; Chen L; Chen G; Guo Z; Yi X; Cao W; Ai X; Zhou C; Li X; Zhao J; Yan X; Yu Q; Si L; Chen Y; Chen C
    BMC Cancer; 2023 Jul; 23(1):686. PubMed ID: 37479966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline
    Siraj AK; Parvathareddy SK; Bu R; Iqbal K; Siraj S; Masoodi T; Concepcion RM; Ghazwani LO; AlBadawi I; Al-Dayel F; Al-Kuraya KS
    Cancer Cell Int; 2019; 19():334. PubMed ID: 31866764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant POLQ and POLZ/REV3L DNA polymerases may contribute to the favorable survival of patients with tumors with POLE mutations outside the exonuclease domain.
    Huang F; Tanaka H; Knudsen BS; Rutgers JK
    BMC Med Genet; 2020 Aug; 21(1):167. PubMed ID: 32838755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.